News & Updates
Filter by Specialty:
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022
byJairia Dela Cruz
Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022
Prepandemic life expectancy rises in older adults, but disability remains constant
28 Mar 2022
byStephen Padilla
Prior to the COVID-19 pandemic, life expectancy at age 70 years has continued to rise across the globe due to reductions in chronic diseases, according to a recent study. However, disability burden persists and indicates the need to improve public health and intervention initiatives to enhance well-being among older adults.
